Analyst Price Targets — BTAI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 23, 2024 7:04 am | Graig Suvannavejh | Mizuho Securities | $1.00 | $0.59 | StreetInsider | Mizuho Reiterates Neutral Rating on BioXcel Therapeutics (BTAI) |
| April 15, 2024 6:44 am | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $2.90 | StreetInsider | BioXcel Therapeutics (BTAI) PT Lowered to $10 at H.C. Wainwright |
| August 15, 2023 2:02 pm | Graig Suvannavejh | Mizuho Securities | $4.00 | $3.98 | Benzinga | Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy |
| January 3, 2023 6:12 am | — | H.C. Wainwright | $73.00 | $21.48 | Benzinga | HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $73 |
| November 11, 2022 8:50 am | — | Guggenheim | $25.00 | $14.82 | Benzinga | Guggenheim Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $25 |
Latest News for BTAI
NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced the closing of its previously announced registered direct offering of 4,500,785 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common…
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale in a registered direct offering of 4,500,785 shares (the…
BioXcel Therapeutics Inc. (NASDAQ: BTAI) shares are down on Friday.
BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potential future development of BXCL501 in opioid withdrawal Opioid use disorder is a global health crisis, affecting approximately 5.9 million adults in the U.S. NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq:…
BioXcel Therapeutics, Inc. (BTAI) Discusses Phase III Results and Advances in Treating Acute Agitation in Alzheimer's Dementia Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BTAI.
U.S. House Trading
No House trades found for BTAI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.